MX2021015156A - Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos. - Google Patents

Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.

Info

Publication number
MX2021015156A
MX2021015156A MX2021015156A MX2021015156A MX2021015156A MX 2021015156 A MX2021015156 A MX 2021015156A MX 2021015156 A MX2021015156 A MX 2021015156A MX 2021015156 A MX2021015156 A MX 2021015156A MX 2021015156 A MX2021015156 A MX 2021015156A
Authority
MX
Mexico
Prior art keywords
pcrv
antibodies
bind
methods
compositions
Prior art date
Application number
MX2021015156A
Other languages
English (en)
Inventor
Christos Kyratsous
Alida Coppi
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021015156A publication Critical patent/MX2021015156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona anticuerpos y fragmentos de unión al antígeno de anticuerpos que se unen a PcrV de Pseudomonas aeruginosa, y métodos para usarlos. De acuerdo con determinadas modalidades, la descripción incluye anticuerpos y fragmentos de unión al antígeno de anticuerpos que se unen a PcrV. Los anticuerpos anti-PcrV y fragmentos de unión al antígeno son útiles para la prevención y el tratamiento de infecciones por P. aeruginosa.
MX2021015156A 2019-06-11 2020-06-10 Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos. MX2021015156A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962860146P 2019-06-11 2019-06-11
PCT/US2020/037008 WO2020252029A1 (en) 2019-06-11 2020-06-10 Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021015156A true MX2021015156A (es) 2022-01-18

Family

ID=71948699

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015156A MX2021015156A (es) 2019-06-11 2020-06-10 Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.

Country Status (16)

Country Link
US (2) US11655286B2 (es)
EP (1) EP3983015A1 (es)
JP (1) JP2022536469A (es)
KR (1) KR20220019755A (es)
CN (1) CN113966343A (es)
AU (1) AU2020292283A1 (es)
BR (1) BR112021023335A2 (es)
CA (1) CA3140075A1 (es)
CL (1) CL2021003215A1 (es)
CO (1) CO2021015254A2 (es)
EA (1) EA202192810A1 (es)
IL (1) IL288727A (es)
MA (2) MA54975B1 (es)
MX (1) MX2021015156A (es)
SG (1) SG11202112462RA (es)
WO (1) WO2020252029A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2776065T (lt) * 2011-11-07 2020-10-12 Medimmune Limited Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekules
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
CN114404614B (zh) * 2022-01-28 2024-04-23 上海交通大学 一种靶向铜绿假单胞菌的免疫脂质体及其制备方法和应用
WO2023236041A1 (zh) * 2022-06-07 2023-12-14 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60216564T2 (de) 2001-01-26 2007-10-11 MCW Research Foundation, Inc., Milwaukee Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
EP2767161B1 (en) 2004-10-19 2018-02-07 Regeneron Pharmaceuticals, Inc. Method for generating an non-human animal homozygous for a genetic modification
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
JP5781765B2 (ja) * 2007-11-30 2015-09-24 カロバイオス ファーマシューティカルズ インコーポレイティッド シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体
CN102137870B (zh) 2008-01-10 2014-09-03 盐野义制药株式会社 抗PcrV抗体
CN104119437A (zh) * 2009-03-11 2014-10-29 盐野义制药株式会社 具有抗绿脓杆菌作用的人源化PcrV抗体
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2012122533A2 (en) 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
LT2776065T (lt) 2011-11-07 2020-10-12 Medimmune Limited Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekules
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
BR112015010240A2 (pt) * 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
SG10201913100WA (en) * 2015-11-30 2020-03-30 Medimmune Ltd Method for preventing or treating nosocomial pneumonia
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
KR20200058525A (ko) 2017-09-29 2020-05-27 리제너론 파아마슈티컬스, 인크. 스타필로코커스 표적 항원 및 보체 성분에 결합하는 이특이적 항원-결합 분자 및 이의 용도

Also Published As

Publication number Publication date
AU2020292283A1 (en) 2021-12-23
US20200392210A1 (en) 2020-12-17
CN113966343A (zh) 2022-01-21
EA202192810A1 (ru) 2022-03-05
MA54975B1 (fr) 2023-08-31
US11655286B2 (en) 2023-05-23
CA3140075A1 (en) 2020-12-17
CL2021003215A1 (es) 2022-09-30
US20230322907A1 (en) 2023-10-12
BR112021023335A2 (pt) 2022-01-04
IL288727A (en) 2022-02-01
JP2022536469A (ja) 2022-08-17
WO2020252029A1 (en) 2020-12-17
CO2021015254A2 (es) 2021-11-19
EP3983015A1 (en) 2022-04-20
KR20220019755A (ko) 2022-02-17
MA54975A1 (fr) 2022-05-31
SG11202112462RA (en) 2021-12-30
MA56205A (fr) 2022-04-20

Similar Documents

Publication Publication Date Title
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2018234793A3 (en) Antibodies
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
MX2021015156A (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2018016364A (es) Anticuerpos anti-pd-l1.
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
MX2020008122A (es) Anticuerpos anti-pd-1.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
WO2019182867A8 (en) Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
AU2018279184A1 (en) Anti-TrkB antibodies
WO2023004477A8 (en) Neutralising antibodies and uses thereof
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
MX2022009130A (es) Anticuerpos anti-e-selectina, composiciones y metodos de uso.